GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Twinrix
Biological: Nimenrix (Meningococcal vaccine 134612)

First Posted Date: 2007-04-25

Last Posted Date: 2018-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 611

Registration Number: NCT00465816

Locations: 🇸🇪
GSK Investigational Site, Örebro, Sweden

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

Phase 3

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: Mencevax™ ACWY
Biological: Meningococcal vaccine GSK134612

First Posted Date: 2007-04-24

Last Posted Date: 2018-06-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1025

Registration Number: NCT00464815

Locations: 🇨🇳
GSK Investigational Site, Tao Yuan County, Taiwan

A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis

Phase 2

Completed

Conditions: Rhinitis, Allergic, Seasonal

First Posted Date: 2007-04-23

Last Posted Date: 2018-08-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT00464568

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

Phase 1

Completed

Conditions: Macular Degeneration
Age-related Macular Degeneration

First Posted Date: 2007-04-20

Last Posted Date: 2012-03-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 29

Registration Number: NCT00463320

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Phase 3

Completed

Conditions: Acellular Pertussis
Streptococcus Pneumoniae Vaccines
Tetanus
Poliomyelitis
Diphtheria
Hepatitis B

Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A
Biological: Prevenar
Biological: Infanrix penta
Biological: Infanrix hexa
Biological: Infanrix IPV Hib
Biological: Infanrix IPV
Biological: Meningitec
Biological: NeisVac-C
Biological: Menitorix